Linked Life Data

15313023

Source:http://linkedlifedata.com/resource/pubmed/id/15313023

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-8-17
pubmed:abstractText
Noradrenaline, not only functions as a synaptic transmitter, but also promotes neural differentiation and regenerative processes. In Parkinson's disease, besides the dopaminergic degeneration, noradrenergic neurons of locus coeruleus origin degenerate as well. Drugs enhancing noradrenergic transmission in the locus coeruleus (e.g. alpha2-adrenoceptor antagonists) have been shown to be neuroprotective against Huntington's and ischemic animal models. However, in Parkinsonian animal models, most of the studies evaluated the worsening of experimental nigral neurodegeneration after locus coeruleus lesions. Here, it has been tested, whether treatment with the selective alpha2-adrenoceptor antagonist, 2-methoxy idazoxan (2.5 mg/kg i.p., twice daily for 5 days), before an experimental lesion to nigra, protects dopaminergic neurodegeneration. Dopaminergic degeneration was produced by 6-hydroxydopamine lesion in the median forebrain bundle. The concentrations of dopamine, 5-hydroxytryptamine and its metabolites were analysed in the various regions of the basal ganglia. The concentrations of noradrenaline and dopamine were measured in the regions innervated by locus coeruleus neurons and in the basal ganglia respectively, after 2-methoxy idazoxan treatment. The Parkinsonian behavior was assessed by catalepsy and activity test. 2-Methoxy idazoxan specifically increased the concentration of noradrenaline in the brain regions, innervated by locus coeruleus neurons. 6-OHDA lesion strongly depleted the concentration of dopamine and its metabolites in the striatum and SN, producing catalepsy and hypoactivity. Multiple treatments with 2-methoxy idazoxan reduced some of the observed neurochemical and behavioral indices of 6-hydroxydopamine-induced Parkinsonism, indicating neuroprotection. Although the mechanism underlying the neuroprotective property remains elusive, the therapeutic usage of alpha2-antagonists might be helpful in slowing the neuronal death and progression of Parkinson's disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0166-4328
pubmed:author
pubmed:issnType
Print
pubmed:day
5
pubmed:volume
154
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
353-63
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15313023-Adrenergic alpha-Antagonists, pubmed-meshheading:15313023-Analysis of Variance, pubmed-meshheading:15313023-Animals, pubmed-meshheading:15313023-Brain Chemistry, pubmed-meshheading:15313023-Catalepsy, pubmed-meshheading:15313023-Disease Models, Animal, pubmed-meshheading:15313023-Dopamine, pubmed-meshheading:15313023-Drug Interactions, pubmed-meshheading:15313023-Hydroxyindoleacetic Acid, pubmed-meshheading:15313023-Idazoxan, pubmed-meshheading:15313023-Male, pubmed-meshheading:15313023-Motor Activity, pubmed-meshheading:15313023-Norepinephrine, pubmed-meshheading:15313023-Oxidopamine, pubmed-meshheading:15313023-Parkinsonian Disorders, pubmed-meshheading:15313023-Rats, pubmed-meshheading:15313023-Rats, Sprague-Dawley, pubmed-meshheading:15313023-Reaction Time, pubmed-meshheading:15313023-Serotonin, pubmed-meshheading:15313023-Statistics, Nonparametric
pubmed:year
2004
pubmed:articleTitle
Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
pubmed:affiliation
Neuropharmacology, Zoological Institute, University of Tuebingen, Auf der Morgenstelle 28E, 72076 Tuebingen, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't